Dorsey:
Not available at the moment http://narsg.uk/stmap_21ojktcc.html sizegenetics video tutorial The FDA submission is based on a trial presented at the American Society for Clinical Oncology meeting in June. Nexavar almost doubled progression-free survival, to a median of 10.8 months in patients treated with it, compared with 5.8 months in control patients. Bayer filed for FDA approval soon after.
    Dorsey写于2022/6/27 14:17:47